Adelson Medical Research Foundation Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2019
NCT03912220
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Adelson Medical Research Foundation | The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

Active Ingredients

Drugs in Phase 2 Trials (2)

maraviroc (selzentry) (1 trial)

nicotinamide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Small Fiber Neuropathy (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2